Mindstate Design Labs operates a clinical-stage AI neuroengineering platform to develop novel therapeutics for mental health conditions. Their Osmanthus platform synthesizes psychoactive effect reports and biochemical data to map the biological basis of emotional and cognitive states. This technology drives the development of pharmaceutical compounds designed to precisely induce specific therapeutic states like empathy or awe.
Funding
$24.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICNR+1Founders
Product
Problem
Current psychedelic drug development lacks a robust translational model to differentiate the nuances between altered states of consciousness, hindering the ability to target specific therapeutic applications. This limitation makes it difficult to predictably design drugs for specific mental health conditions.
Solution
Mindstate Design Labs is developing Osmanthus, a neurotech AI platform that combines natural history, natural language processing, and biochemical data to create a predictive model for the precision design of altered states of consciousness. The platform aims to map the biological basis of the varieties of psychedelic experience to enable the design of modified conscious states. Their pipeline uses psychedelic "primer" compounds together with non-psychedelic "probe" compounds that modulate the altered state of consciousness produced by the primer. The Osmanthus screening platform has identified six probe candidates to date, each with potentially unique therapeutic utility when combined with the lead primer.
Target Audience
The primary target audience includes researchers and pharmaceutical companies involved in psychedelic drug development, seeking a more targeted and predictable approach to creating therapeutics for mental health conditions.
Features
- Osmanthus: A target discovery and phenotypic screening platform for altered conscious states.
- AI-powered predictive model for designing modified conscious states.
- Pipeline based on psychedelic "primer" compounds and non-psychedelic "probe" compounds.
- Identification of probe candidates with unique therapeutic utility.
- Integration of natural history, natural language processing, and biochemical data.